Evaluation of serum and tissue levels of VAP-1 in colorectal cancer by Ward, Stephen T et al.
 
 
Evaluation of serum and tissue levels of VAP-1 in
colorectal cancer
Ward, Stephen; Weston, Christopher; Shepherd, Emma; Hejmadi, Rahul; Ismail, Tariq;
Adams, David
DOI:
10.1186/s12885-016-2183-7
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Ward, ST, Weston, CJ, Shepherd, EL, Hejmadi, R, Ismail, T & Adams, DH 2016, 'Evaluation of serum and tissue
levels of VAP-1 in colorectal cancer', BMC Cancer, vol. 16, no. 1, 154. https://doi.org/10.1186/s12885-016-2183-
7
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 01/03/2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
RESEARCH ARTICLE Open Access
Evaluation of serum and tissue levels of
VAP-1 in colorectal cancer
Stephen T. Ward1*, Christopher J. Weston1, Emma L. Shepherd1, Rahul Hejmadi2, Tariq Ismail2
and David H. Adams1
Abstract
Background: The endothelial adhesion molecule, vascular adhesion protein-1 (VAP-1, AOC3) promotes lymphocyte
recruitment to tumours, although the contribution that VAP-1 makes to lymphocyte recruitment in human colorectal
cancer (CRC) is unknown. VAP-1 exists in circulating soluble form (sVAP-1). A previous study demonstrated elevated
sVAP-1 levels in CRC patients. The aim of this study was to confirm this finding and study the differences in tissue VAP-1
expression between CRC and healthy tissues.
Methods: sVAP-1 levels were measured in the serum of 31 patients with CRC and 31 age- and sex-matched controls.
Tissue VAP-1 levels were measured by immunohistochemistry, quantitative real-time PCR and Western blotting.
Results: The mean sVAP-1 level ± SD was significantly lower in the CRC group compared with the control group
(399 ± 138 ng/ml versus 510 ± 142 ng/ml, P = 0.003). Tissue VAP-1 protein and mRNA levels were significantly lower in
CRC compared with normal colon tissue. VAP-1 immunostaining was practically absent from CRC.
Conclusions: VAP-1 is downregulated in human CRC and although the molecular basis of this down regulation is not
yet known, we suggest it may be part of a mechanism used by the tumour to prevent the recruitment of anti-tumour
immune cells. Our data contradicts the findings of others with regard sVAP-1 levels in patients with CRC. Possible
reasons for this are discussed.
Keywords: VAP-1, AOC3, Colorectal Cancer, Tumor Markers
Background
Colorectal cancer (CRC) is the third most common cause
of cancer-related deaths in the UK and United States [1, 2].
Lymphocyte infiltration in human CRC is associated with
favourable outcome, both in terms of overall survival and
recurrence-free survival [3]. More recent analyses have
shown that assessment of CD8+ and memory CD45RO+
lymphocyte infiltration rivals the prognostic ability of the
standard TNM staging system [4].
Lymphocytes are recruited to tissues from blood via bind-
ing to vessels in the target tissue mediated by interactions
between specific receptors on the lymphocyte surface and
ligands on the endothelium. These interactions involve
several families of adhesion molecules including integrins
and immunoglobulin superfamily members and selectins
and carbohydrate-bearing ligands. The atypical endothelial
adhesion molecule vascular adhesion protein-1 (VAP-1,
AOC3) has been reported to be increased in inflamed
mucosal vessels in the gut where it is believed to promote
the recruitment of leucocytes [5].
VAP-1 mediates adhesion via heavily sialidated side
chains but it also functions as a cell surface expressed
ectoenzyme—a primary amine oxidase. As such it deami-
nates primary amines to form the corresponding aldehyde,
ammonia and hydrogen peroxide, although the physio-
logical substrates are not well defined. VAP-1 was origin-
ally characterised by a monoclonal antibody (mAb 1B2)
that was capable of inhibiting lymphocyte adhesion to high
endothelial venules (HEV) and immobilised purified VAP-
1 protein [6] but it subsequently transpired that the
enzymatic activity of VAP-1 is also involved in its ability to
promote transendothelial migration.
In addition to its ability to promote recruitment to the
gut via its expression on mucosal vessels, VAP-1 has also
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been implicated in the recruitment of lymphocytes to
several human tumours including head and neck cancer
and hepatocellular carcinoma where VAP-1 expressed on
tumour endothelium was shown to support lymphocyte
binding [7, 8]. In murine models of melanoma and lymph-
oma, tumours were smaller in VAP-1 knock-out mice
compared to wild-type littermates [9] as a consequence of
reduced myeloid suppressor cell recruitment. Both MDSC
(myeloid-derived suppressor cells) and regulatory T cells
are recruited to CRC where they inhibit the anti-tumour
immune response, thereby promoting tumour progres-
sion. The contribution of VAP-1 to the recruitment of
lymphocytes to CRC is unknown. Immunohistochemical
studies have demonstrated weak expression of VAP-1 in
Peyer’s patches and lamina proprial vessels of the gut with
increased staining in inflammatory bowel disease. The
staining is typically not as intense as that seen for lymph
node and tonsillar HEV, or that observed in other tissues,
most notably the hepatic sinusoid [8].
VAP-1 also exists in soluble form, probably generated
through cleavage of the membrane-bound protein, and can
be found in the sera of healthy human subjects. In contrast
to other soluble adhesion molecules, soluble VAP-1 (sVAP-
1) levels are not consistently raised in association with
inflammatory diseases but rather associated with particular
conditions including inflammatory liver disease and dia-
betes. Increased levels have been reported in one study in
CRC compared to controls with reduced levels associated
with progressive disease [10], while levels in patients with
hepatocellular carcinoma are not significantly raised above
controls [11]. A large study has shown an association
between sVAP-1 levels and all-cause mortality in CRC,
although this was only after adjustment for multilevel con-
founding variables [12].
The aim of this study was to confirm the reported
elevated levels of sVAP-1 in patients with CRC compared
with controls and determine if differences observed in
sVAP-1 levels are reflected by changes in tissue VAP-1 ex-
pression. As the infiltration of specific lymphocyte subsets
in CRC has a profound effect on prognosis, alterations in
the expression pattern of VAP-1 may provide a means of
cancer-specific lymphocyte recruitment.
Methods
Patients and samples
Stored serum samples from a historical cohort of adults
referred to the colorectal clinic at the University Hospital
Birmingham NHS (National Health Service) Foundation
Trust, Birmingham, UK were used for measurement of
sVAP-1 levels. Patients had been recruited into a previous
study evaluating serum tumour markers for CRC, the de-
tails of which have been reported in full elsewhere [13, 14].
Patients were eligible to be recruited if they were aged 18
or over and had been referred to the colorectal clinic for
evaluation and investigation of lower gastrointestinal symp-
toms. Recruited patients had a serum sample taken and the
results of examination, investigations and the subsequent
diagnosis were recorded. Patients had given consent for
serum samples to be used in the future for the purpose of
evaluation of diagnostic tests and new potential biomarkers.
Of 962 patients who had given consent for future use of
stored serum samples, 31 patients had proven CRC (‘cases’).
Serum from 31 age-, sex-, and ethnic group-matched
patients from the remaining 931 patients who were proven
to not have CRC formed the control group. Matching was
performed by calculation of the general dissimilarity coef-
ficient of Gower, using ‘R’ (R foundation for Statistical
Computing, Austria) and the e1071 package [15].
Tissue samples were obtained from patients under-
going resection for CRC having given informed consent
at the University Hospital Birmingham NHS Foundation
Trust. Fresh pieces of tumour tissue and strips of
colonic tissue, a minimal distance of 10 cm from the
tumour, were taken with the help of an experienced
pathologist.
Ethics statement
Serum samples were collected from a previous study evalu-
ating CRC tumour markers. Full ethical approval had been
obtained from North Birmingham Research Ethics Com-
mittee in October 2004 (Ref: 04/Q2704/29) covering use of
the samples for this study. Patients had given formal written
consent for collection and storage of the serum samples.
Ethical approval was obtained for the collection of tissue
samples from the Local Research & Ethics Committee
(LREC South Birmingham, reference 2003/242, renewed
2012). All patients who donated tissue samples had given
formal written consent.
Enzyme immunoassay for sVAP-1
Serum sVAP-1 was measured by time-resolved immuno-
fluorometric assay at BioTie Therapies Corp., Finland. A
biotin-conjugated monoclonal anti-human VAP-1 anti-
body was adsorbed onto a microtiter plate. Detection of
bound serum VAP-1 was performed using a different
europium-conjugated anti-human VAP-1 antibody. Time-
resolved fluorescence was measured using a fluorometer
(Victor2Multilabel Counter, PerkinElmer) at 615 nm.
Serum VAP-1 concentration was quantified on the basis
of a reference sample of highly purified human serum
VAP-1 (Biovian Ltd).
Immunohistochemistry and immunofluorescence
Formalin-fixed and paraffin-embedded tissues were
deparaffinised and rehydrated by passing the sections
through fresh solutions of Clearene (Leica GmBH,
Germany) and graduated alcohols. Sections for immuno-
histochemistry were incubated with 0.3 % hydrogen
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peroxide solution in methanol and all sections under-
went antigen retrieval by microwaving in pre-heated
EDTA buffer (0.37 g EDTA in 1 l distilled water, pH 8.0,
0.05 % Tween 20) for 15 min. Sections were blocked
with 10 % casein solution for 30 min and then incubated
with either anti-AOC3 antibody (Rabbit polyclonal,
HPA000980, Sigma-Aldrich Ltd, UK) at 1 in 100 dilution
or an isotype control antibody at equal concentration
(Dako Ltd, UK) for 1 h at room temperature. The anti-
AOC3 antibody had been developed and validated by
the Human Protein Atlas [16]. Tissue sections for im-
munofluorescence were incubated with primary anti-
bodies against both AOC3 and the endothelial cell
marker CD31 (Mouse IgG1, Clone 9G11, R&D Systems,
UK). The sections were then washed twice in TBS con-
taining 0.1 % Tween-20 and incubated with an HRP-
conjugated development system (Vector ImmPress, Vec-
tor Labs) or fluorescent secondary antibody (Alexa-Fluor
546 goat anti-rabbit IgG and Alexa-Fluor 633 goat anti-
mouse IgG1, Life Technologies, UK) both at 1 in 500 di-
lution for 20 min at room temperature. Following a final
wash with TBS/0.1 % Tween-20, immunohistochemistry
sections were visualised using Novared (Vector Labs Inc,
USA) and counter-stained with Meyer’s haematoxylin
(Dako Ltd, UK) before mounting in DPX (Leica GmBH,
Germany). Immunofluorescent sections were counter-
stained with DAPI and mounted with Mowiol (Sigma-Al-
drich Ltd, UK). Immunocytochemistry was performed on
cultured human colonic endothelial cells, below passage 4,
using anti-AOC3 and anti-CD31 antibodies as described
above for tissue immunofluorescence. Tissue expression
was visualised using a Leica DM6000 (chromogenic) micro-
scope or an LSM510 confocal microscope (Zeiss GmBH,
Germany) and the manufacturer’s software.
Quantitative real-time PCR
RNA was extracted from snap-frozen tissue samples using
the Qiagen RNeasy minikit as per manufacturer’s instruc-
tions with on-column DNA digestion. The RNA concen-
tration was adjusted to 100 μg/ml following assessment of
RNA quantity and quality by UV absorbance at 260/
280 nm (Nanophotometer, Implen GmBH, Germany).
RNA was reverse transcribed from 3 μg RNA using the
iScript kit (Biorad Inc, USA) and quantitative real-time
PCR was performed using the LightCycler 480 (Roche,
UK). Primers and probes were designed using the Real-
Time Ready software (Roche) for VAP-1 and two house-
keeping gene expression assays: GUSB (glucuronidase,
beta) and IPO8 (importin-8). The GUSB assay was ob-
tained from Roche (Universal ProbeLibrary Reference
Gene Assay). Other probes were obtained from Roche and
reverse-phase purified primers were manufactured by
Altabioscience (Birmingham, UK). The following probes
and intron-spanning primer sequences were used:
VAP-1 mRNA levels were expressed relative to
GUSB and IPO8 mRNA as calculated by the Roche
E-method [17]. Amplification conditions were: Pre-
incubation at 95 °C for 10 min followed by 60 cycles
of denaturation at 95 °C for 10 s, annealing at 55 °C
for 30 s and extension at 72 °C for 1 s. Analysis was
performed on 8 samples of matched colon and CRC.
Control reactions containing no reverse transcriptase
or no RNA were negative. Differences in relative gene
expression between colon and matched CRC samples
were tested for statistical significance using a two-
tailed unpaired t-test.
Western blotting
Protein was extracted from snap-frozen tissue by incuba-
tion in ice-cold lysis buffer (CellLytic MT, 20 μl/mg tissue,
Sigma-Aldrich Ltd, UK) containing a proteinase inhibitor
cocktail (Sigma-Aldrich Ltd, UK) and 5 U/ml DNase I
(Roche, UK). The tissue was mechanically dissociated in
the buffer solution using the GentleMACS tissue dissocia-
tor (Miltenyi Biotec Ltd, UK). Samples were pelleted and
the supernatant collected. Protein concentrations were de-
termined against a bovine serum albumin standard using
a bicinchoninic acid assay and sample protein concentra-
tions adjusted to 2 mg/ml by dilution in cell lysis buffer.
40 μg protein per sample was incubated at 98 °C for
1 min in SDS-PAGE sample buffer containing 10 mM
beta-mercapto-ethanol, resolved on a 12 % SDS-PAGE gel
and then transferred to a nitrocellulose membrane. Mem-
branes were blocked in 5 % non-fat milk dissolved in PBS
containing 0.1 % Tween-20 for 1 h at room temperature.
Membranes were subsequently incubated overnight at 4 °
C with either rabbit anti-human VAP-1 (Sigma-Aldrich
Ltd, UK) at1 in 1000 dilution, anti-goat GUSB (R&D Sys-
tems Ltd, UK) at1 in 200 dilution or anti-mouse GAPDH
(Sigma-Aldrich Ltd, UK) at1 in 10,000 dilution followed
by a 1 h room temperature incubation with HRP-
conjugated anti-rabbit/goat/mouse antibodies (Dako Ltd,
UK; 1 in 2500). Protein bands were detected with the
PicoWest ECL system (Pierce, USA). Protein band dens-
ities were calculated using ImageJ v1.46r (NIH, USA) and
differences in band densities between colon and matched
CRC samples were tested for statistical significance using
a two-tailed unpaired t-test.
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Flow cytometry
Fresh tissue was washed in RPMI containing penicillin
(10,000 U/ml), streptomycin (10,000 μg/ml), L-glutamine
(29.2 mg/ml), gentamicin (5 mg/ml) and amphotericin
(125 μg/ml, Life Technologies Ltd, UK). The tissues were
cut into small pieces and digested in a solution containing
collagenase (C2-22, VWR International Ltd, UK) for 1 h at
37 °C. The mixture was then passed through a fine mesh
to remove debris. An immunomagnetic depletion of
EpCAM-expressing cells was performed using EpCAM
microbeads and MACS columns (Miltenyi Biotec Ltd,
UK) as this is a common cell contaminant in endothelial
cell cultures. Positive immunoselection of endothelial cells
was then performed using CD31 microbeads and cells
were resuspended in endothelial basal medium (Lonza
Ltd, UK) supplemented with the aforementioned antibi-
otics. Cultured endothelial cells, below passage four, from
both human colon and CRC were labelled withanti-CD31
(Life Technologies Ltd, UK) and anti-VAP-1 (Clone: TK8-
14, Conjugated in our laboratory to APC using the Lynx
system; Serotec, UK). HEK293 cells which had been trans-
fected with a GFP-VAP1 construct were used as a positive
control for the VAP-1 antibody (as described in Weston et
al, JNT 2013 [18]).
Results
Serum sVAP-1 levels are lower in patients with CRC
compared with controls
sVAP-1 levels were measured in the serum of 31 patients
with proven CRC and 31 age-, sex- and ethnic group-
matched control patients who had been investigated for
lower gastrointestinal symptoms and proven not to have
CRC. The distribution of sVAP-1 levels was normally
distributed and therefore differences in the group means
was tested for statistical significance using a two-tailed
unpaired t-test. The mean sVAP-1 level ± one standard
deviation was 399 ± 138 ng/ml in the CRC group
compared with 510 ± 142 ng/ml in the control group
(P = 0.003, Fig. 1).
Expression of tissue VAP-1 protein and mRNA
Western blotting was used to analyse VAP-1 protein ex-
pression in tissue lysates generated from tissue taken
from patients with CRC or matched normal controls.
Levels of VAP-1 protein were consistently lower in CRC
tissue when compared to normal tissue in 8 matched
samples (Fig. 2a,b). Densitometric analysis of VAP-1
protein bands relative to GUSB bands showed that this
difference was highly statistically significant. Equal pro-
tein loading was demonstrated by similar GUSB protein
band densities for each lane.
Quantitative real-time PCR revealed lower VAP-1 gene
(AOC3) expression in CRC compared with matched colon
for 7 out of 8 samples (Fig. 2c), consistent with the protein
expression data. A panel of 11 different housekeeping
genes were compared on 8 matched samples analysed
using GeNORM, Normfinder and Bestkeeper software to
determine the best housekeeping genes with the least vari-
ation between tumour and normal colon [Unpublished
data]. AOC3 expression was therefore calculated relative
to GUSB and IPO8, both of which displayed stable expres-
sion between samples.
Immunohistochemistry
VAP-1 tissue expression was determined using immuno-
histochemical staining of sections from 10 colon and
matched CRC samples of different disease stages, all were
moderate grade adenocarcinomas. In normal colon VAP-1
was detected in the muscularis mucosae and in vessels in
the lamina propria and submucosa (Fig. 3). In contradis-
tinction, VAP-1 staining was practically absent from CRC,
apart from occasional weak cytoplasmic staining of the
tumour epithelium. A section of CRC with adjoining
colon on both sides revealed VAP-1 expression within the
colon with an abrupt disappearance at the border between
the colon and cancer tissue (Fig. 4). High magnification
microscopy of colon tissue suggested that most of the
VAP-1 staining detected in vessels was detected in cells
Fig. 1 Serum VAP-1 (sVAP-1) levels measured in patients with CRC
and controls. The bars indicate the mean ± one standard deviation.
Differences between groups were tested for statistical significance
using a two-tailed unpaired t-test
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surrounding the endothelium, such as pericytes and
smooth muscle cells. This was confirmed by dual-colour
immunofluorescence, demonstrating localisation of VAP-1
to α-SMA-positive cells rather than CD31-positive cells
(Fig. 5a,b). Cultured endothelial cells from human colon
expressed cell-surface CD31 but no VAP-1 neither on the
cell surface nor in the cytoplasm (Fig. 5c).
Discussion
We have shown that circulating sVAP-1 levels are sig-
nificantly lower in patients with CRC compared with
controls. This surprising finding directly contradicts a
previous study reporting elevated serum sVAP-1 levels
in patients with CRC compared to healthy control
subjects [10]. In this earlier study, the highest sVAP-1
levels were found in early stage disease while lower
levels predicted lymphatic and hepatic metastasis. Serum
sVAP-1 levels were generally lower than in our study
and this may represent different methods of measure-
ment. In their study, a commercially available ELISA kit
was used (Bender MedSystems GmbH, Austria) whereas
in our study a well validated, sensitive immunofluoro-
metric assay was used (Biotie Therapies Corp, Finland).
In gastric cancer serum sVAP-1 levels measured using
the commercial kit are also reportedly elevated com-
pared with controls, with the level declining as the dis-
ease progresses [19]. In all studies, the control group has
been matched with the case group for age and sex which
suggests the method of measurement as a source for the
disparity in the results. Another possibility relates to the
different study populations: Japanese for the two studies
reporting elevated sVAP-1 levels in cancer patients
compared to a largely caucasian population (>90 %) in
our study. We used a control group of patients referred
to the colorectal clinic for various lower gastrointestinal
symptoms as detailed previously [14]. This control group
is therefore different to the healthy controls described in
the other studies [10, 19], but more relevant as a com-
parator group with CRC patients. Increased levels of
sVAP-1 have been reported in inflammatory diseases
such as ectopic eczema [20], liver cirrhosis [11] and
multiple sclerosis [21]. There is notably no increase in
sVAP-1 levels in inflammatory bowel disease compared
to healthy controls [22], despite increased tissue levels of
VAP-1. A study using the Biotie immunofluorometric
assay reported an association between sVAP-1 and all-
cause mortality in CRC [12]. This study did not compare
sVAP-1 levels between patients with CRC and control
patients without CRC. There was also no such associ-
ation by univariate analysis, only when adjusted for
multilevel confounding variables.
Having detected lower levels of sVAP-1 in CRC we
wanted to see if this reflected reduced tissue expression.
There are very few previous studies of VAP-1 tissue expres-
sion by CRC. A recent paper reports increased VAP-1 in
patients with CRC but the validity of the observations was
reduced by staining in the negative controls and the finding
of VAP-1 in the lumen of CRC tissue [12]. The antibody
used in this study (Santa Cruz Biotechnology Inc, USA)
differs from the one used in our study and could provide
one explanation for observed differences in positive VAP-1
staining. We were scrupulous in our choice of controls and
compared CRC with normal colon tissue where tissue
staining has been reported before. We have also compared
Fig. 2 a VAP-1 protein expression by Western blot for 8 normal colon (NC) and matched CRC samples. The vertical black line indicates separate
gels. b Protein band densitometry of VAP-1/GUSB shows a statistically significant reduction in VAP-1 protein expression in CRC tissue compared
with matched colon. c VAP-1 gene expression by 8 normal colon and CRC samples shows a statistically significant reduction in VAP-1 mRNA
expression in CRC tissues compared with matched colon, relative to GUSB and IPO8 expression. The bars indicate the mean ± one standard
deviation. Differences between groups were tested for statistical significance using a two-tailed unpaired t-test
Ward et al. BMC Cancer  (2016) 16:154 Page 5 of 8
the positive immunostaining of the HPA000980 antibody in
the liver with other well-validated anti-VAP-1 antibodies
such as TK8-14 and similar staining was observed (unpub-
lished observations). This allowed us to be sure that the
staining we observed was specific for the tumours. Consist-
ent with the reduced soluble levels of VAP-1 in CRC, we
detected a marked reduction in VAP-1 expression as deter-
mined by gene expression analysis, protein immunoblotting
and immunohistochemistry by CRC compared with normal
colon tissue. Indeed there was minimal detection of VAP-1
in CRC. In tissue stained at the same time under the same
conditions we detected VAP-1 in normal colon in vessels
associated with pericytes and smooth muscle cells as de-
scribed before. This is consistent with the stated conclusion
of the Human Protein Atlas that there is an absence of
VAP-1 staining in CRC [16].
Increased or strong VAP-1 expression has been detected
on some cancers including head and neck and liver
Fig. 3 Paraffin-embedded sections from 3 matched normal colon (NC)
and CRC samples demonstrating positive VAP-1 staining in the lamina
propria and submucosa of the colon with only weak staining in CRC
stroma. Magnification x200. VAP-1 staining is brown-red, haematoxylin
staining is blue. MM=muscularis mucosae; SM = submucosal;
LP = lamina propria; St = tumour stroma; Epi = tumour epithelium
Fig. 4 VAP-1 expression in flanking normal colon (NC) tissue
abruptly disappears at the border with CRC tissue. Dot-dash line
marks the border between NC and CRC. Magnification x200. VAP-1
staining is brown-red, haematoxylin staining is blue
Fig. 5 Dual-colour immunofluorescent staining of sections of normal
colon tissue and cultured colonic endothelial cells. Magnification
x630. a VAP-1 staining is present in SMA+ cells of vessels in sections
of colonic mucosa. b VAP-1 staining does not co-localise with CD31
+ endothelial staining of vessels in sections of colonic mucosa.
Right-most images are digitally magnified x3. Yellow staining
represents autofluorescence from erythrocytes. c Positive CD31
staining (left) and absent VAP-1 staining (right) of cultured colonic
endothelial cells
Ward et al. BMC Cancer  (2016) 16:154 Page 6 of 8
cancers where it has been proposed that VAP-1 supports
the recruitment of lymphocytes [7]. In a melanoma mouse
model, tumour vessels expressed VAP-1 and VAP-1
knock-out mice demonstrated an impaired ability to form
new tumour vessels [9]. In this model, inhibition of VAP-1
reduced tumour-infiltration by CD8+ T cells and MDSCs
leading to the conclusion that VAP-1 can support tumour
progression via the recruitment of immunosuppressive
cells. However, in humans and in keeping with our find-
ings, a reduction of VAP-1 expression by immunohisto-
chemistry was found on vessels in human melanoma
tissue compared to peritumoral vessels [23]. In contrast to
melanoma tissue, increased VAP-1 immunoreactivity has
recently been demonstrated in microvessels in human con-
junctival tumours [24] and in human breast cancer, tumour
VAP-1 mRNA expression is associated with oestrogen
receptor expression and improved prognosis [25, 26]. In
contrast, amine oxidase activity was lower in malignant
compared to benign tumours in a rat breast cancer model
[27]. Thus the role of VAP-1 in tumour progression is likely
to depend both on the host and tumour type.
Conclusions
Our data suggest that VAP-1 is downregulated in human
CRC because we found reduced circulating protein levels,
lack of detectable mRNA and VAP-1 protein in tumours.
Furthermore we were unable to detect VAP-1 in primary
tumour endothelial cells isolated from human CRC. The
molecular basis of this down regulation is not yet known
but it may be part of a mechanism activated by the
tumour to prevent the recruitment of anti-tumour im-
mune cells. Given that sVAP-1 is predominantly produced
by the hepatic vasculature it was surprising that sVAP-1
levels were reduced in CRC and this suggests the cancer
may also have systemic effects in suppressing VAP-1 ex-
pression. Whether these low levels of sVAP-1 will prove to
have any use as markers of prognosis remains to be seen
but the level of overlap between the CRC patients and
matched patients would make this unlikely.
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